Arthneeti

Vimta Labs Q1 FY27 Share Price & Earnings Call Analysis

₹484.90-6.71% today
Market cap
₹2,166 Cr
P/E
26.79
ROE
18.87%
PEG
1.43
Price to sales
5.18
Debt to equity
0.01
52W high / low
₹725 / ₹381
Sales growth (5Y)
14.27%
EBITDA margin
34.66%
Net profit margin
19.36%
Promoter holding
35.64%
Sales (last year)
₹419 Cr

Incorporated in 1990, Vimta Labs Ltd is a contract research and testing services provider[1]

Guidance scorecard · Q1 FY27 call

What Vimta Labs Ltd's management guided
and where it ranks in Healthcare Services

#15of 33 in
Healthcare Services
Revenue20–40%MarginsFlatCapexPlannedFundraisingWhat management saidOrder bookRising

RevenueQ1 FY27 call

20–40%
  • Vimta Labs aims for 20% to 25% growth in sales/revenue for the full year (Q1 was impacted by Middle East crisis).
  • Despite Q1 challenges, the company remains optimistic and confident about growth over the next few quarters and the full year.
  • The company's various business units are growing at almost double the industry's CAGR (8%-11%).
  • Positive enquiry trends quarter-on-quarter signal improving demand conditions.
  • Expansion in pharma services, especially export to the U.S., is expected to contribute significantly.
  • New biologics segment expected to contribute meaningfully from the third year onwards.

2 more points from Vimta Labs Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Vimta Labs Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Vimta Labs has a planned capex of approximately INR 80 crores for FY27.
  • Around INR 20 crores have already been spent on the Biologics segment, with a remaining INR 10 crores planned for this year.
  • The capex includes about INR 40 crores invested in the Electronics and Electrical testing segment.
  • The majority of the INR 80 crores capex is for routine operations across various business units, with only a portion allocated to Biologics.
  • Capital investments are phased based on business visibility, customer demand, and project needs.

2 more points from Vimta Labs Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Vimta Labs Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

Rising
  • The company has secured its first order in the new Biologics vertical, with commercialization having begun in Q1 FY27.
  • The timeline for conversion of other client discussions into orders is variable, depending on project stages.
  • The management expressed a positive outlook on the enquiry trend, indicating a healthy pipeline both domestically and internationally, especially in the U.S. pharma services market.
  • The company is confident about maintaining growth despite challenges like the Middle East crisis affecting some business segments.
Full Q1 FY27 analysis
Full Healthcare Services ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Healthcare Services
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Aster DM Quality Care LtdGood growth
    3
See all potential multibaggersWhere does Vimta Labs Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Healthcare Services companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹903 Cr—
240%+Flat₹583 Cr22.2
3Aster DM Quality Care Ltd20–40%Up 2%+₹58,782 Cr162.9
420–40%Up 0–2%₹1,730 Cr17.5
520–40%Up 0–2%₹580 Cr11.9
620–40%Flat₹1.13L Cr53.9

Sign up free to see every company in the sector ranking and track Vimta Labs Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services ranking

Financials of Vimta Labs Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Vimta Labs Ltd

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +36.98%36.92%36.89%36.89%36.76%36.70%36.67%35.99%35.89%35.85%35.66%35.64%
FIIs +2.88%5.13%5.16%3.31%3.81%3.66%3.49%4.33%4.59%4.89%4.41%5.07%
DIIs +1.49%1.50%1.49%0.00%1.15%1.43%1.42%0.87%0.11%0.13%0.37%0.48%
Public +58.65%56.45%56.45%59.80%58.28%58.20%58.42%58.80%59.40%59.12%59.55%58.79%
No. of Shareholders19,95718,55019,05420,11421,15626,18330,82955,93354,46751,62350,19050,484

Financials of Vimta Labs Ltd

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +647373758590949810299109109112
Expenses +48504749555761646864707274
Operating Profit17232626303333343434393738
OPM %26%31%36%35%35%37%35%35%34%35%36%34%34%
Other Income +0-1-1-1-152230343
Interest1110010000000
Depreciation98888109101011131313
Profit before tax8131617202825252623292828
Tax %25%25%24%26%24%23%27%25%24%25%27%26%25%
Net Profit +691212152218192018212121
EPS in Rs1.342.142.792.773.444.844.124.244.473.944.734.714.61

Financials of Vimta Labs Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +116138154183213181209276315289344407429
Expenses +99119127138155151156196222195222266280
Operating Profit17192745583053809494122142149
OPM %15%14%18%25%27%17%25%29%30%33%35%35%35%
Other Income +111123103-45710
Interest1125542232211
Depreciation11101016202123233133354449
Profit before tax7817263582855645590104108
Tax %24%23%36%36%28%17%25%26%26%25%25%25%
Net Profit +56111625721414741677880
EPS in Rs1.141.452.403.725.731.574.819.2910.689.2615.1317.3517.99
Dividend Payout %44%34%0%27%17%0%21%11%9%11%7%12%

Financials of Vimta Labs Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital4444444444499
Reserves118122132148167169190229276310374448482
Borrowings +42644402632301915199314
Other Liabilities +212342404039495465617910287
Total Liabilities146176222232237245273306360394467562593
Fixed Assets +888888140135131128162168166230305299
CWIP06530421701259381823
Investments00000666600215
Other Assets +5882809299105122138174170198237256
Total Assets146176222232237245273306360394467562593

Financials of Vimta Labs Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +15-1243339243759876194147
Cash from Investing Activity +-8-16-39-24-16-20-32-38-57-76-76-130
Cash from Financing Activity +-91913-8-23-1-5-16-11-2-16-10
Net Cash Flow-12-21131519-1727
Free Cash Flow8-17-169231052037-141747
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit96%4%107%86%85%101%84%94%106%81%95%121%

Financials of Vimta Labs Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days821001011111001171281029311011395
Inventory Days158213183209199191140154195260210203
Days Payable6677184148115114139108124878879
Cash Conversion Cycle174236100172184194128147164283235219
Working Capital Days1099922627864898778989683
ROCE %6%7%11%17%21%6%14%24%24%20%25%25%

Guidance history

How Vimta Labs Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →20–40%FlatPlanned—Rising
Q4 FY26 call →10–20%FlatNone plannedNone planned—
Q3 FY26 call →10–20%FlatPlanned——
Q2 FY26 call →10–20%FlatPlanned—Rising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

19out of 100

Momentum score · price trend

19 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−32.2%21%
Last 6 months+6.1%64%
Last 3 months−20.4%21%

The price is 44.7% below its all-time high of ₹877.2 (5 Sept 2025). Stocks more than 20% below their peak have their score halved, so 38 became 19.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Vimta Labs Ltd: 0.4 × 21 + 0.4 × 64 + 0.2 × 21 = 38, halved to 19 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Vimta Labs Ltd's management said in earlier quarters

Others in Healthcare Services this season

  • Rainbow Childrens Medicare Ltd (Q2 FY27)

    Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how

  • Narayana Hrudayalaya Ltd (Q2 FY27)

    Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27

  • Artemis Medicare Services Ltd (Q2 FY27)

    Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service

  • Max Healthcare Institute Ltd (Q2 FY27)

    Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio

Compare:vs Apollo Hospitals Enterprise Ltdvs Manipal Health Enterprises Ltdvs Max Healthcare Institute Ltd